Chronic Remote Ischemic Conditioning in Vascular Cognitive Impairment: A Dose Escalation Study
Launched by AUGUSTA UNIVERSITY · Dec 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a treatment called remote ischemic conditioning, which involves temporarily restricting blood flow to an arm to see how it affects brain health and cognitive function in older adults. The goal is to learn how different doses of this treatment influence certain blood markers related to brain health in people who have age-related changes in their brain's white matter, as seen on MRI scans. This study is important as it will help researchers prepare for a larger trial to see if this treatment can help improve cognitive function.
To be eligible for the trial, participants need to be at least 55 years old and have had an MRI in the past six months showing only mild to moderate age-related brain changes. They should be able to walk independently and perform daily activities without assistance. Participants will be asked to use a special device during the treatment, and they will need to understand the study and give their consent to take part. If you're interested in helping with this important research, this trial offers a chance to contribute to our understanding of brain health in aging.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥55 years
- • 2. Head MRI in the past 6 months showing no more than moderate age related cerebral white matter changes (Fazekas score 0-2).
- • 3. Able to walk without assistance \& independently perform basic activities of daily living.
- • 4. Able to understand this study and agree for a valid consent.
- Exclusion Criteria:
- • Prior non-lacunar (cortical) stroke. 2. Unable to cooperate with the use of the conditioning device. 3. Confounding illness that might interfere with the interpretation of results (such as active malignancy or multiple sclerosis).
- • 4. Contraindication to transient arm ischemia in either arm (such as symptomatic peripheral artery disease).
About Augusta University
Augusta University is a prominent academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a leader in medical education and patient care, Augusta University conducts rigorous clinical studies aimed at improving treatment outcomes and enhancing patient quality of life. The university’s commitment to interdisciplinary collaboration fosters a dynamic research environment, enabling the exploration of novel therapies and interventions across a wide range of medical fields. With a focus on ethical standards and patient safety, Augusta University strives to translate scientific discoveries into tangible benefits for the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Augusta, Georgia, United States
Patients applied
Trial Officials
Carol Smith, RN
Study Director
Wellstar MCG Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported